Research Overview

Our lab is dedicated to improving the lives of children and young adults with sickle cell disease, with a particular focus on relieving pain. We study ways to optimize pain treatment, including the use of ketamine and buprenorphine, as well as approaches that address psychosocial and health-related social needs. Our work also explores brain health and learning, genetic modifiers of disease complications, equitable access to care and therapies, and sustainable sickle cell care around the world. Across these efforts, we are committed to advancing research and clinical environments rooted in justice, curiosity, and belonging.

Research Background

Natasha M. Archer, MD, MPH, is a pediatric hematologist at Boston Children’s Hospital, an assistant professor of pediatrics at Harvard Medical School, and director of the Sickle Cell Program at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. Her research focuses on improving pain management for children and young adults with sickle cell disease, including studies of ketamine and buprenorphine. She also investigates genetic modifiers of sickle cell complications, brain health, and the influence of social and economic factors on health outcomes. Her work extends to global health, including efforts to strengthen sickle cell care in resource-limited settings and research on the relationship between hemoglobin and malaria. Dr. Archer leads the clinical working group of the international INHERENT network and is committed to mentoring the next generation of researchers and advancing equity in care and research.

Publications

  1. Further evidence supporting the global use of hydroxyurea. Blood Adv. 2023 10 10; 7(19):5968-5969. View Abstract
  2. Increasing COVID-19 Vaccination Rates for Children With Sickle Cell Disease. Pediatrics. 2023 10 01; 152(4). View Abstract
  3. Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling. Nat Commun. 2023 09 20; 14(1):5850. View Abstract
  4. F-erythrocytes promote Plasmodium falciparum proliferation in sickle cell disease. Am J Hematol. 2023 10; 98(10):1598-1605. View Abstract
  5. Ketamine use for management of vaso-occlusive pain in pediatric sickle cell disease. Pediatr Blood Cancer. 2023 05; 70(5):e30254. View Abstract
  6. Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease? Am J Hematol. 2023 04; 98(4):564-565. View Abstract
  7. Diversity, equity, and inclusion: Moving from ambition to action. Pediatr Blood Cancer. 2023 Apr; 70(4):e30197. View Abstract
  8. Patient Controlled Analgesia for Vaso-Occlusive Episodes in Children: A Retrospective Study. J Pain Symptom Manage. 2023 05; 65(5):e409-e415. View Abstract
  9. Does fetal hemoglobin inhibit the malarial parasite Plasmodium falciparum? Am J Hematol. 2022 09; 97(9):E325-E327. View Abstract
  10. Enablers and barriers to newborn screening for sickle cell disease in Africa: results from a qualitative study involving programmes in six countries. BMJ Open. 2022 03 09; 12(3):e057623. View Abstract
  11. A seat at the table: A perspective on participation of Black individuals in clinical trials. Pediatr Blood Cancer. 2022 05; 69(5):e29617. View Abstract
  12. A call to start hydroxyurea by 6 months of age and before the advent of sickle cell disease complications. Pediatr Blood Cancer. 2022 02; 69(2):e29423. View Abstract
  13. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Br J Haematol. 2021 11; 195(4):e150-e153. View Abstract
  14. The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies. Am J Hematol. 2021 11 01; 96(11):E416-E420. View Abstract
  15. Will the changing therapeutic landscape meet the needs of patients with sickle cell disease? Lancet Haematol. 2021 05; 8(5):e306-e307. View Abstract
  16. A systematic review of ketamine for the management of vaso-occlusive pain in sickle cell disease. Pediatr Blood Cancer. 2021 07; 68(7):e28989. View Abstract
  17. Autoimmune hemolytic anemia complicated by parvovirus infection. Blood. 2021 02 25; 137(8):1130. View Abstract
  18. End the pain: Start with antiracism. Am J Hematol. 2021 01; 96(1):4-6. View Abstract
  19. Association of Blood Type With Postsurgical Mucosal Bleeding in Pediatric Patients Undergoing Tonsillectomy With or Without Adenoidectomy. JAMA Netw Open. 2020 03 02; 3(3):e201804. View Abstract
  20. Fetal hemoglobin does not inhibit Plasmodium falciparum growth. Blood Adv. 2019 07 23; 3(14):2149-2152. View Abstract
  21. Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ hereditary xerocytosis red cells. Am J Physiol Cell Physiol. 2019 08 01; 317(2):C287-C302. View Abstract
  22. Capacity building and networking to make newborn screening for sickle cell disease a reality in Haiti. Blood Adv. 2018 11 30; 2(Suppl 1):54-55. View Abstract
  23. Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition. Proc Natl Acad Sci U S A. 2018 07 10; 115(28):7350-7355. View Abstract
  24. Knowledge of Blood Group Decreases von Willebrand Factor Panel Testing in Children. Hemasphere. 2017 12; 1(1):e3. View Abstract
  25. Pediatric sialoblastoma: Evaluation and management. Int J Pediatr Otorhinolaryngol. 2016 Aug; 87:44-9. View Abstract
  26. 2015 Clinical trials update in sickle cell anemia. Am J Hematol. 2015 Oct; 90(10):934-50. View Abstract
  27. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci. 2015; 52(5):256-72. View Abstract
  28. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci. 2015 Aug 14; 1-17. View Abstract
  29. An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome? Pediatr Blood Cancer. 2016 Feb; 63(2):196-201. View Abstract
  30. The utility of the DDAVP challenge test in children with low von Willebrand factor. Br J Haematol. 2015 Sep; 170(6):884-6. View Abstract
  31. Use of a fever fast track tool to reduce time to antibiotic dose in febrile pediatric oncology patients. J Clin Oncol. 2014 Oct 20; 32(30_suppl):222. View Abstract
  32. A diagnostic role for dense cells in sickle cell disease. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14647-8. View Abstract
  33. Hereditary xerocytosis revisited. Am J Hematol. 2014 Dec; 89(12):1142-6. View Abstract
  34. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014 Apr 01; 120(7):1068-75. View Abstract
  35. Building partnerships to target sickle cell anemia in Africa. Am J Hematol. 2013 Dec; 88(12):983. View Abstract
  36. Haiti: how visiting educators can help the most. Acad Med. 2013 Mar; 88(3):299-300. View Abstract
  37. Perspective: postearthquake haiti renews the call for global health training in medical education. Acad Med. 2011 Jul; 86(7):889-91. View Abstract

Contact Natasha Archer

Fax: (617) 730-0641